Status:
UNKNOWN
Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)
Lead Sponsor:
Taipei Medical University WanFang Hospital
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-60 years
Brief Summary
Vascular endothelial growth factor (VEGF)-C is recognized as a tumor lymphangiogenic factor based on the effects of activated VEGFR3 on lymphatic endothelial cells. VEGFR3 has been proposed as a speci...
Eligibility Criteria
Inclusion
- patients who were diagnosed acute myeloid leukemia
Exclusion
- patients who were diagnosed other type leukemia
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01195506
Start Date
September 1 2010
Last Update
October 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Medical University - WanFang Hospital
Taipei, Taiwan